Prescribing of antipsychotics in UK primary care: A cohort study

BMJ Open

Volumn 4, Issue 12, 2014, Pages

  Marston, Louise ^a   Nazareth, Irwin ^a   Petersen, Irene ^a   Walters, Kate ^a   Osborn, David P J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DRUG INDICATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERSONALITY DISORDER; PRESCRIPTION; PRIMARY MEDICAL CARE; PSYCHOSIS; SCHIZOPHRENIA; SLEEP DISORDER; TREATMENT DURATION; UNITED KINGDOM; VERY ELDERLY; ADOLESCENT; CHILD; CLINICAL PRACTICE; INAPPROPRIATE PRESCRIBING; MENTAL DISORDERS; MOOD DISORDERS; PRIMARY HEALTH CARE; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; COHORT STUDIES; DEMENTIA; DRUG PRESCRIPTIONS; FEMALE; GREAT BRITAIN; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84920531868     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006135     Document Type: Article

References (29)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
2. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study (electronic article). BMJ 2008;337:a1227.
3. National Institute for Health and Care Excellence. Depression: the treatment and management of depression in adults (update). CG90 2009a. http://guidance.nice.org.uk/CG90 (accessed May 2014).
4. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96.
5. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24:1577-600.
6. National Institute for Health and Care Excellence. Borderline personality disorder: treatment and management. CG78 2009b. http://www.nice.org.uk/CG78 (accessed May 2014).
7. The Health Improvement Network. London, 2014. http://csdmruk.cegedim.com/ (accessed May 2014).
8. Clinical Practice Research Datalink (CPRD) website. Crown Copyright 2014. http://www.cprd.com/intro.asp (accessed Oct 2014).
9. Lis Y, Mann RD. The VAMP research multi-purpose database in the UK. J Clin Epidemiol 1995;48:431-43.
10. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the North. London: Croom Helm, 1988.
11. Booth N. What are the Read codes? Health Libr Rev 1994;11:177-82.
12. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press, 2014. http://www.medicinescomplete.com (accessed May 2014).
13. Blak BT, Thompson M, Dattani H, et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-5.
14. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf 2013;22:64-9.
15. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidem Drug Saf 2009;18:76-83.
16. Nazareth I, King M, Haines A, et al. Accuracy of diagnosis of psychosis on general practice computer system. BMJ 1993;307:32-4.
17. Hardoon S, Hayes JF, Blackburn R, et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PLoS One 2013;8:e82365.
18. Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidem Drug Saf 2009;18:704-7.
19. Walters K, Rait G, Griffin M, et al. Recent trends in the incidence of anxiety diagnoses and symptoms in primary care. PLoS ONE 2012;7:e4167.
20. Rait G, Walters K, Griffin M, et al. Recent trends in the incidence of recorded depression and depressive symptoms in primary care. Br J Psychiat 2009;195:520-4.
21. Stata Corporation. Stata statistical software: release 13. College Station, TX: Stata Corporation, 2013.
22. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
23. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 2003;56:569-75.
24. Prah P, Petersen I, Nazareth I, et al. National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. Pharmacoepidem Drug Saf 2012;21:161-9.
25. Department of Health. The use of antipsychotic medication for people with dementia: time for action. London: Department of Health, 2009.
26. U.S. Food and Drug Adminstration. Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances, 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm (accessed May 2014).
27. The NHS Information Centre PaPCS. Prescribing compliance: a review of the proportion of prescriptions dispensed. 2011. http://www.hscic.gov.uk/pubs/presccompliance (accessed May 2014).
28. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10:e1001403.
29. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: metaanalyses of randomized controlled trials. J Clin Psychiatry 2010;71:14-25.